- Coordinator
- Universitetet I Oslo, Norway
- Runs
- 1 October 2026 to 30 September 2031
- Status
- Running
- EU funding
- €2.5m
- Total cost
- —
- Partners
- 3 organisations in 2 countries
- Type
- European Research Council grant
- Grant agreement
- 101264507
What the project is doing
In the project's own words, from its summary on CORDIS.
Escherichia coli is a bacterial model organism with broad applications in molecular genetics and is clinically the most significant cause of bacterial infections. Domesticated E. coli have been the subject of fundamental research on bacterial evolution and genetics for decades, yet we have limited understanding of the mechanisms regulating natural E. coli populations that near-universally colonise the human gut. Evidence points to the existence of strong equilibria of lineage prevalence and synchronised appearance of novel genotypes across host populations, yet how such equilibria emerge and are maintained remains unclear.
ACES aims to fill this knowledge gap through a combination of innovative sampling frames and in vivo experiments with the latest long-read sequencing and analytical techniques, including targeted PacBio shotgun metagenomics and simulation-based modelling. These technological advances provide an opportunity to obtain a refined characterisation of all genomic variation occurring in an E. coli population, including gene content, capsular antigens, plasmidome and phageome.
The main hypothesis of ACES is that key accessory genomic elements augment the genetic capabilities encoded by the core genome and together control the ecological and evolutionary success of individual genotypes over time. ACES will develop models to assess whether observed population equilibria arise as a consequence of the success strategies driven by the accessory elements. The knowledge generated by ACES will have broad implications for understanding bacterial ecology and evolution, and our approach will pave the way to similar studies outside of bacterial model organisms in the future.
ACES will also facilitate future prediction of the consequences of population interventions, such as novel antibiotics, probiotics and vaccines, informing the development of new means to alleviate the ongoing global antibiotic resistance crisis.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitetet I Oslo | Oslo | Norway | Coordinator |
| Universitetet I Tromsoe - Norges Arktiske Universitet | Tromso | Norway | Participant |
| Genome Research Limited Lbg | Saffron Walden | United Kingdom | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI